摘要
目的 筛选出愈肠宁方（黄芪多糖、黄芪皂苷、苦参碱、氧化苦参碱组成）用于治疗溃疡性结肠炎（ulcerative colitis，UC）的最佳给药方式，为其制剂设计提供依据。方法 采用三硝基苯磺酸(TNBS)诱导大鼠UC模型，实验分为阳性组、正常组、模型组、给药组等6组，其中给药组按给药方式分为灌胃组(Ⅰ)、灌肠组(Ⅱ)、黄芪组分灌胃＋苦参组分灌肠组(Ⅲ)3组，分别观察治疗后大鼠结肠黏膜组织形态学变化，测定计算结肠肠重系数、血清中肿瘤坏死因子α（TNF-α）、结肠黏膜组织中髓过氧化物酶（MPO）的水平。结果 与模型组比较，Ⅱ、Ⅲ组均能明显改善结肠黏膜组织损伤、降低肠重系数（P<0.05，P<0.01），并显著降低TNF-α及 MPO水平（P<0.01），而Ⅰ组仅能降低TNF-α水平（P<0.01）。结论 愈肠宁方对该模型有较好的疗效，3种给药方式中以Ⅲ组效果最佳，为该方的制剂设计提供参考。
Abstract
OBJECTIVE To evaluate administration route of Yuchangning to treat ulcerative colitis（UC）by the pharmacodynamics， and to provide a scientific basis for the design on praeparatum. METHODS UC was induced in rat trinitro-benzene-sulfonic acid（TNBS）. Yuchangning was given to rats by intragastric administration (Ⅰ) ， coloclysis administration (Ⅱ)， and composition of radix astragali in intragastric administration plus composition of radix sophorae flavescentis in coloclysis (Ⅲ). The change of morphous of tunica mucosa coli was observed. The coefficient of colon weight，concentration of TNF-α in serum and MPO in tunica mucosa coli was measured. RESULTS Compared with the model group， both group Ⅱand Ⅲ improved the injury of tunica mucosa coli，decreased coefficient of colon weight（P<0.05，P<0.01），decrease the level of MPO and TNF-α（P<0.01）. RouteⅠ only decreased the level of TNF-α. CONCLUSION Among the three administration ways， Ⅲ is the best，which provides the experimental basis for the design on praeparatum of Yuchangning.
关键词
愈肠宁 /
给药方式 /
溃疡性结肠炎
{{custom_keyword}} /
Key words
Yuchangning /
administration way /
ulcerative colitis /
comparision of pharmacological action
{{custom_keyword}} /
谢兴亮 盛艳梅 曾敏 杨明.
愈肠宁方不同给药方式对三硝基苯磺酸致大鼠溃疡性结肠炎的影响[J]. 中国药学杂志, 2010, 45(12): 906-908
XIE Xing-ling;SHENG Yn-mei;ZENG Min;YNG Ming.
Effect of Different Administrations of Yuchangning on Ulcerative Colitis in Rats Induced by TNBS[J]. Chinese Pharmaceutical Journal, 2010, 45(12): 906-908
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SHENG Y M， XIE X L， YANG M，et al. A study on components of Yuchangning as a new herbal recipes[J]. Her Med（医药导报），2008，27（3）：258-261.
[2] CHEN Y Q， DONG F L， MA G T. Experimental study of ulcerative colitis in rats incluced by trinitrobenzene sulfonic acid[J]. J Tongji Univ (Med Sci)（同济大学学报：医学版)，2006，27（6）：31-33.
[3] LI J H， HE X F， XU X M， et al. Effect of glucoside tripterygium total on activities of NO and iNOS in TNBS induced colitis rat[J]. Her Med（医药导报），2004，23（5）：298-230.
[4] LI G F， CHEN J H， LAI Z S， et al. Effect of chitosan capsule filled with dexamethasone liposome lyophilized powder on colitis in rats[J]. Chin Pharm J（中国药学杂志），2006，41(15)： 1145-1149.
[5] ZHENG N X，RUAN J X，ZHANG Y X，et al.Intestinal absorption of an acidic polysaccharide from Liuwei Dihuang decoction in mice[J]. Chin Pharmacol Bull（中国药理学通报），2000，16（4）：403-405.
[6] YOSHIKAWA H， TAKADA K， MURANISH S. Molecular weight-dependent lymphatic transfer of exogenous macromolecules from large intestine of renal insufficiency rats[J]. Pharm Res， 1992，9（9）：1195-1198.
[7] TRNOVEC T， HRMOVA M. Immunomodulator polysaccharides： chemistry， disposition and metabolism[J]. Biopharm Drug Dispo，1993，14（3）：187-198.
[8] HUANG H P，LIU C X， LI Y L， et al. Study on absorption kinetics of astragalosideⅣ in rats intestines[J]. China J Chin Mat Med(中国中药杂志)，2008，33(13)：1609-1611.
[9] WANG X H， HUANG S K. Pharmacokinetics and pharmacodynamics of matrine and oxymatrine[J]. Acta Pharm Sin(药学学报)，1992，27（8）：572.
[10] YANG M， FENG Y， XU D S， et al. Technical lines for advanced TCM drug release system[J]. World Sci Technol(Mod Tradit Chin Med Mat Med)(世界科学技术：中医药现代化)， 2006，8(5)：10-15.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(781 KB)
